News

LSKB is attending ASCO in Chicago at the McCormick Center June 2-7th. We will be meeting with key leading oncologists from across the globe to discuss late stage development of apatinib mesylate in gastric cancer, colorectal cancer, and hepatocellular carcinoma. Contact arlo.mcginn@lskbiopharma.com for more information.

READ MORE

Salt Lake City– LSK BioPharma (LSKB) and the University of Utah’s Huntsman Cancer Institute (HCI) today announced an exclusive license agreement for LSKB to develop and commercialize HCI-1401, an orally bioavailable, small molecule, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). “BTK inhibitors are an exciting

READ MORE

Salt Lake City, UT, June 6, 2012 - LSK BioPartners today announced the initiation of a Phase 1/2A dose escalation and safety trial of apatinib mesylate (YN968D1) with the enrollment of the first three patients of the first dose cohort. This is the first clinical

READ MORE